Bank of New York Mellon’s ADMA Biologics ADMA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $10.5M | Sell |
1,250,658
-104,785
| -8% | -$955K | ﹤0.01% | 2001 |
|
|
2026
Q1 | $12.2M | Sell |
1,355,443
-47,769
| -3% | -$754K | ﹤0.01% | 1820 |
|
|
2025
Q4 | $25.6M | Sell |
1,403,212
-20,238
| -1% | -$341K | ﹤0.01% | 1395 |
|
|
2025
Q3 | $20.9M | Sell |
1,423,450
-75,866
| -5% | -$1.3M | ﹤0.01% | 1531 |
|
|
2025
Q2 | $27.3M | Buy |
1,499,316
+30,707
| +2% | +$626K | 0.01% | 1352 |
|
|
2025
Q1 | $29.1M | Sell |
1,468,609
-52,557
| -3% | -$909K | 0.01% | 1291 |
|
|
2024
Q4 | $26.1M | Buy |
1,521,166
+147,748
| +11% | +$2.78M | ﹤0.01% | 1408 |
|
|
2024
Q3 | $27.5M | Buy |
1,373,418
+606,874
| +79% | +$9.44M | 0.01% | 1400 |
|
|
2024
Q2 | $8.57M | Buy |
766,544
+49,631
| +7% | +$416K | ﹤0.01% | 2039 |
|
|
2024
Q1 | $4.73M | Sell |
716,913
-62,989
| -8% | -$344K | ﹤0.01% | 2355 |
|
|
2023
Q4 | $3.53M | Sell |
779,902
-25,798
| -3% | -$95.4K | ﹤0.01% | 2542 |
|
|
2023
Q3 | $2.88M | Buy |
805,700
+16,551
| +2% | +$63.7K | ﹤0.01% | 2595 |
|
|
2023
Q2 | $2.91M | Buy |
789,149
+113,341
| +17% | +$420K | ﹤0.01% | 2625 |
|
|
2023
Q1 | $2.24M | Buy |
675,808
+27,928
| +4% | +$96.5K | ﹤0.01% | 2739 |
|
|
2022
Q4 | $2.51M | Buy |
647,880
+67,053
| +12% | +$207K | ﹤0.01% | 2724 |
|
|
2022
Q3 | $1.41M | Buy |
580,827
+81,017
| +16% | +$194K | ﹤0.01% | 3037 |
|
|
2022
Q2 | $990K | Buy |
499,810
+416,409
| +499% | +$819K | ﹤0.01% | 3217 |
|
|
2022
Q1 | $153K | Buy |
83,401
+36,967
| +80% | +$57.7K | ﹤0.01% | 4314 |
|
|
2021
Q4 | $65K | Hold |
46,434
| – | – | ﹤0.01% | 4462 |
|
|
2021
Q3 | $52K | Sell |
46,434
-13,316
| -22% | -$18.7K | ﹤0.01% | 4432 |
|
|
2021
Q2 | $96K | Sell |
59,750
-145,662
| -71% | -$256K | ﹤0.01% | 4224 |
|
|
2021
Q1 | $362K | Sell |
205,412
-3,363
| -2% | -$7.7K | ﹤0.01% | 3840 |
|
|
2020
Q4 | $406K | Buy |
208,775
+14,953
| +8% | +$31.4K | ﹤0.01% | 3715 |
|
|
2020
Q3 | $463K | Sell |
193,822
-23,015
| -11% | -$63.1K | ﹤0.01% | 3528 |
|
|
2020
Q2 | $635K | Buy |
216,837
+23,183
| +12% | +$66.6K | ﹤0.01% | 3355 |
|
|
2020
Q1 | $558K | Buy |
193,654
+32,001
| +20% | +$111K | ﹤0.01% | 3307 |
|
|
2019
Q4 | $647K | Buy |
161,653
+27,901
| +21% | +$122K | ﹤0.01% | 3458 |
|
|
2019
Q3 | $595K | Buy |
133,752
+51,576
| +63% | +$216K | ﹤0.01% | 3439 |
|
|
2019
Q2 | $317K | Buy |
82,176
+21,545
| +36% | +$95.1K | ﹤0.01% | 3792 |
|
|
2019
Q1 | $230K | Buy |
60,631
+5,803
| +11% | +$20.5K | ﹤0.01% | 3837 |
|
|
2018
Q4 | $131K | Hold |
54,828
| – | – | ﹤0.01% | 3924 |
|
|
2018
Q3 | $340K | Hold |
54,828
| – | – | ﹤0.01% | 3789 |
|
|
2018
Q2 | $247K | Buy |
54,828
+35,791
| +188% | +$178K | ﹤0.01% | 3875 |
|
|
2018
Q1 | $87K | Buy |
+19,037
| New | +$75.7K | ﹤0.01% | 4087 |
|
|
2017
Q4 | – | Sell |
-21,344
| Closed | -$66K | – | 4354 |
|
|
2017
Q3 | $66K | Hold |
21,344
| – | – | ﹤0.01% | 4059 |
|
|
2017
Q2 | $79K | Buy |
+21,344
| New | +$85.7K | ﹤0.01% | 4066 |
|
Other funds holding ADMA
AAP
YIH
JAM
MCM
Bank of New York Mellon's ADMA Position: Q2 2026 in Review
Bank of New York Mellon reduced its ADMA Biologics (ADMA) stake by 7.7% in Q2 2026, selling an estimated $955K and leaving 1,250,658 shares worth $10.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2001.
Bank of New York Mellon first reported a position in ADMA in Q2 2017 and has held it in 36 quarters since. The position peaked at $29.1M in Q1 2025. 139 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.
- Bank of New York Mellon held 1,250,658 shares of ADMA Biologics worth $10.5M as of Q2 2026.
- Bank of New York Mellon sold 104,785 ADMA Biologics shares in Q2 2026, an estimated $955K.
- ADMA Biologics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2001 holding.
- Bank of New York Mellon first reported a position in ADMA Biologics in Q2 2017 and has held it in 36 quarters since.
- Bank of New York Mellon's ADMA Biologics position peaked at $29.1M in Q1 2025.
- 139 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.